Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 1,811 | 200 | 1,603 |
| Samples | 287 | 47 | 238 |
| Peptides | 258 | 42 | 223 |
Function
RBMS3 · RNA binding motif single stranded interacting protein 3
This gene encodes an RNA-binding protein that belongs to the c-myc gene single-strand binding protein family. These proteins are characterized by the presence of two sets of ribonucleoprotein consensus sequence (RNP-CS) that contain conserved motifs, RNP1 and RNP2, originally described in RNA binding proteins, and required for DNA binding. These proteins have been implicated in such diverse functions as DNA replication, gene transcription, cell cycle progression and apoptosis. The encoded protein was isolated by virtue of its binding to an upstream element of the alpha2(I) collagen promoter. The observation that this protein localizes mostly in the cytoplasm suggests that it may be involved in a cytoplasmic function such as controlling RNA metabolism, rather than transcription. Multiple alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2010].
Isoforms & Proteins
7 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 209 amino-acid changes on canonical ENST00000383767 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in RBMS3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in RBMS3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| Glioblastoma | 4/98 4% | 0/0 0% |
| Endometrial Carcinoma | 4/42 10% | 15/612 2% |
| Melanoma | 3/210 1% | 41/1899 2% |
| Other Solid Cancers | 2/94 2% | 28/1515 2% |
| Hodgkins Lymphoma | 1/16 6% | 1/122 1% |
| Colorectal Carcinoma | 10/143 7% | 32/3239 1% |
| Gastric Carcinoma | 2/74 3% | 21/1809 1% |
| Plasma Cell Myeloma | 3/44 7% | 1/305 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 8/810 1% |
| Germ Cell Tumour | 0/25 0% | 2/169 1% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 9/1390 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Glioma | 0/52 0% | 11/2127 1% |
| Medulloblastoma | 0/0 0% | 2/450 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 3/752 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 9/2550 0% |
| Head and Neck Carcinoma | 0/85 0% | 5/1574 0% |
| Biliary Tract Carcinoma | 0/54 0% | 3/950 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Breast Carcinoma | 0/144 0% | 10/3264 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 5/2534 0% |
| Neuroendocrine Tumour | 1/154 1% | 1/577 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Hepatocellular Carcinoma | 0/46 0% | 5/2210 0% |
| Prostate Carcinoma | 0/13 0% | 4/2105 0% |
| Pancreatic Carcinoma | 2/89 2% | 1/1611 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
Mutation Distribution
Where RBMS3 is mutated · all tissues, split by cell line vs tissue
How many mutations in RBMS3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 1,811 mutations in RBMS3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|